September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

Taeun Kang: Beyond Traditional ‘Blood Thinners’ – Cardiovascular and Thrombosis Therapeutics

Taeun Kang/LinkedIn

May 9, 2026, 14:55

Taeun Kang: Beyond Traditional ‘Blood Thinners’ – Cardiovascular and Thrombosis Therapeutics

Taeun Kang, Founder and Chief Growth Officer of Manhattan Signal, shared a post on LinkedIn:

“Pause and Note – Cardiovascular and Thrombosis Therapeutics

As shared previously, I have been spending more time independently researching cardiovascular therapeutics, thrombosis prevention, and emerging RNA-based medicines simply out of personal interest and curiosity around where the biotech and pharmaceutical industries may be heading.

Based on my research, below is a high-level market snapshot that I thought some people in biotech/pharma – and especially families impacted by cardiovascular conditions – may also find interesting.

It appears that the landscape is evolving beyond traditional ‘blood thinners’ into much more targeted next-generation cardiovascular approaches.

Current leaders still include major anticoagulants and antiplatelet therapies such as:

Eliquis
Xarelto
Pradaxa
Plavix
Brilinta

At the same time, increasing attention appears to be shifting toward:

Lp(a)-lowering therapies
FXIa inhibitors
RNA-based cardiovascular medicines
Precision thrombosis prevention

Particularly interesting is the growing focus around Lipoprotein(a) [Lp(a)], which continues drawing attention in cardiovascular risk and thrombosis research.

Some major programs currently being watched across the industry include:

Pelacarsen – Novartis
Olpasiran – Amgen
Zerlasiran – Silence Therapeutics
Lepodisiran – Eli Lilly

I also found it fascinating how multiple modalities are emerging simultaneously, including:

siRNA
Antisense oligonucleotides (ASO)
FXIa inhibition pathways

The intersection of RNA therapeutics, cardiovascular medicine, and preventative care may become one of the more important biotech themes of the next decade.

Question: How can we speed up these new emerging therapies?

To be continued”

Taeun Kang: Beyond Traditional 'Blood Thinners' - Cardiovascular and Thrombosis Therapeutics